| Description | |
|---|---|
| Catalogue Number | 14-420 |
| Brand Family | Upstate |
| Trade Name |
|
| Description | MEK1 Protein, inactive, 50 µg |
| Overview | N-terminal GST, and Cterminal His6-tagged, recombinant full-length human MEK1 |
| Product Information | |
|---|---|
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Inactive, N-terminal GST & C-terminal His6-tagged, recombinant full-length human MEK1, for use in Kinase Assays. |
| Key Applications |
|
| Biological Information | |
|---|---|
| Source | expressed in E.coli |
| Specific Activity | For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme. |
| Entrez Gene Number |
|
| Entrez Gene Summary | The protein encoded by this gene is a member of the dual specificity protein kinase family, which acts as a mitogen-activated protein (MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. This protein kinase lies upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. As an essential component of MAP kinase signal transduction pathway, this kinase is involved in many cellular processes such as proliferation, differentiation, transcription regulation and development. |
| Gene Symbol |
|
| Protein Target | MEK1 |
| Purification Method | glutathione-agarose followed by Ni2+/NTA-agarose |
| Target Sub-Family | STE |
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: Q02750 # Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases. SIZE: 393 amino acids; 43439 Da SUBUNIT: Interacts with MORG1 (By similarity). Interacts with Yersinia yopJ. PTM: Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity. & Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway. DISEASE: SwissProt: Q02750 # Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio- cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant. SIMILARITY: SwissProt: Q02750 ## Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily. & Contains 1 protein kinase domain. |
| Molecular Weight | 71kDa |
| Product Usage Statements | |
|---|---|
| Quality Assurance | routinely evaluated by phosphorylation of MBP (Catalog # 13-104) substrate in vitro |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | 6 months at -70°C |
| Packaging Information | |
|---|---|
| Material Size | 50 µg |